Amgen 4Q Revenues: $6.8 billion (flat) 4Q Earnings: $1.6 billion (-15%) FY Revenues: $26.3 billion (+1%) FY Earnings: $6.6 billion (+11%) Comments: Revenues benefited from a 4% increase in product sales, offset by lower other revenue from Amgen’s COVID-19 manufacturing collaboration. Product sales growth was driven by double-digit volume growth for several products including: Lumakras/Lumykras (sotorasib), Nplate (romiplostim), Evenity (romosozumab-aqqg), Repatha (evolocumab), Pars...